5-Amino-1MQ: promising mouse metabolism data, no human dose

## What is it? 5-Amino-1MQ, also called 5A1MQ, is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It appears in the related-compounds section of this catalog but is not itself a peptide. NNMT participates in nicotinamide metabolism; inhibiting it is a research strategy, not an established fat-loss treatment. [1,2]

## What do studies show? In diet-induced obese mice, an early study reported lower body weight and white-fat mass after subcutaneous 5-Amino-1MQ. A later 28-day mouse study reported dose-related limits on fat gain and improvements in glucose handling and liver markers. These are preclinical outcomes. They do not establish that the product causes weight loss or is safe in humans. Some investigators in the later study disclosed ties to a company developing this approach, which reinforces the need for independent clinical testing. [1,2]

## Safety No controlled human trial in the cited evidence establishes adverse-event rates, interactions, reproductive effects, or long-term consequences. A lack of obvious adverse effects in a short mouse experiment is not proof of human safety. [1,2]

## How much? One mouse experiment used 20 mg/kg subcutaneously three times daily for 11 days; another examined different mouse exposures over 28 days. These are animal research regimens, not adult doses. No safe and effective human 5-Amino-1MQ dose or independently verifiable exact-product anecdotal protocol was identified. [1,2]